NCT02126579 2024-02-28
MEL60
University of Virginia
Phase 1/2 Completed
Clinical Trials
3 trialsNCT00960752 2021-08-13
Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00821652 2015-01-08
Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination
Icahn School of Medicine at Mount Sinai
Phase 1 Completed